Steven Cohen's VRDN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2.34 M shares of Viridian Therapeutics, Inc. (VRDN) worth $43.04 M, representing 0.05% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in VRDN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 2.02 M shares. Largest reduction occurred in Q3 2022, reducing 503,693 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Viridian Therapeutics (VRDN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Viridian Therapeutics (VRDN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +2.02 M | Add 625.82% | 2.34 M | $18.37 |
| Q1 2026 | +68,551 | Add 26.96% | 322,836 | $19.56 |
| Q4 2025 | +254,285 | New Buy | 254,285 | $31.12 |
| Q3 2025 | -104,043 | Sold Out | 0 | $0.00 |
| Q2 2025 | -100,659 | Reduce 49.17% | 104,043 | $13.98 |
| Q1 2025 | +204,702 | New Buy | 204,702 | $13.48 |
| Q4 2024 | -34,627 | Sold Out | 0 | $0.00 |
| Q3 2024 | +34,627 | New Buy | 34,627 | $22.75 |
| Q4 2023 | -439,191 | Sold Out | 0 | $0.00 |
| Q3 2023 | +439,191 | New Buy | 439,191 | $15.34 |
| Q2 2023 | -57,100 | Sold Out | 0 | $0.00 |
| Q1 2023 | -202,991 | Reduce 78.05% | 57,100 | $25.44 |
| Q4 2022 | -26,616 | Reduce 9.28% | 260,091 | $29.21 |
| Q3 2022 | -503,693 | Reduce 63.73% | 286,707 | $20.51 |
| Q2 2022 | +490,400 | Add 163.47% | 790,400 | $11.57 |
| Q1 2022 | -172,864 | Reduce 36.56% | 300,000 | $18.49 |
| Q4 2021 | -137,136 | Reduce 22.48% | 472,864 | $19.77 |
| Q3 2021 | +214,466 | Add 54.22% | 610,000 | $16.45 |
| Q1 2021 | +395,534 | New Buy | 395,534 | $16.71 |
Steven Cohen's Viridian Therapeutics Investment FAQs
Steven Cohen first purchased Viridian Therapeutics, Inc. (VRDN) in Q1 2021, acquiring 395,534 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Viridian Therapeutics, Inc. (VRDN) for 20 quarters since Q1 2021.
Steven Cohen's largest addition to Viridian Therapeutics, Inc. (VRDN) was in Q2 2026, adding 2,343,208 shares worth $43.04 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,343,208 shares of Viridian Therapeutics, Inc. (VRDN), valued at approximately $43.04 M.
As of the Q2 2026 filing, Viridian Therapeutics, Inc. (VRDN) represents approximately 0.05% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Viridian Therapeutics, Inc. (VRDN) was 2,343,208 shares, as reported at the end of Q2 2026.